KPV: The Alpha-MSH Fragment With Real Mouse Data and Zero Human Trials

Three amino acids. Lysine, proline, valine. That’s the whole molecule. Snip them off the tail end of alpha-MSH, a hormone your body already makes to control skin pigmentation and turn down inflammation, and you get KPV. Same anti-inflammatory signal, at least in mice. None of the tan.

It’s not FDA-approved. It’s not close. But on July 23, 2026, KPV lands on a federal advisory committee’s docket anyway, one line in a list of compounds regulators are deciding how to treat before anyone has run a single human trial on it.

What is KPV and how does it relate to alpha-MSH?

Trim alpha-MSH down to its last three building blocks and what remains is KPV (C1). Alpha-MSH is a longer peptide your pituitary gland makes. Brzoska and colleagues laid out the case for KPV’s anti-inflammatory role in a 2010 review (C2). The pitch is straightforward. Alpha-MSH does two separate jobs in the body, pigmentation and immune signalling, and the anti-inflammatory job might not need the whole molecule to run.

Does KPV share alpha-MSH’s mechanism or does it work differently?

Here’s the question nobody’s fully answered. KPV keeps much of alpha-MSH’s anti-inflammatory activity without triggering the pigmentation response (C10). That’s the pitch that gives KPV its own name instead of being treated as a leftover fragment. But nobody knows why KPV keeps the anti-inflammatory effect without the tanning effect, the reason it works that way hasn’t been found. Nobody knows what KPV latches onto inside the body to produce its effect. The separation itself is real in the data. The mechanism behind it is a blank page.

The lab data: a switch, and what flips it

In immune cells, both in dishes and in animal models, there’s a molecular switch called NF-κB that gets flipped on when the body ramps up inflammation. When that switch is on, immune cells flood the area with signals that drive inflammation. KPV turns that switch down, and the output of those signals drops with it (C3). It also slows down the pull that draws immune cells toward a site of damage (C3). That’s the whole mechanistic case, and it’s a coherent one. What it isn’t: a study in a person.

What does the animal evidence for KPV in gut inflammation actually show?

Kannengiesser and colleagues ran the foundational study in 2008, giving KPV to mice with induced gut inflammation (C4). More KPV meant less inflammation and less tissue damage in those mice, a clean dose-response in a single study (C5). It’s also one study, one lab, one species, back in 2008, with nothing published since that replicates it in a different model or a different animal. Eighteen years is a long stretch for nobody to check.

The chain from that mouse gut to a human one has three links, and none of them are built yet. First, species: does a mouse colon respond to KPV the way a human colon does? Second, dose: what curve applies in a body many times the size of a mouse’s? Third, delivery: how does KPV reach the gut lining intact in the first place? One study answers none of these. It answers a narrower question, in mice, about tissue scores under a microscope.

Human evidence: there isn’t any

This is the part that matters most, so it gets said plainly. No registered controlled human trial exists for KPV in any inflammatory condition. No human pharmacokinetic study has been published (C6). That means nobody knows how KPV behaves once it’s inside a person: how much gets absorbed, how long it stays active, where it ends up in the body. Bioavailability, half-life, tissue penetration, all unknown, not because the answer is unfavourable, but because the study hasn’t been run.

Does it even survive the trip?

Swallow a tripeptide and it has to get past stomach acid, then a gut wall lined with enzymes built specifically to break peptides down into single amino acids for absorption. That’s what digestion does to protein, on purpose. Whether KPV survives that gauntlet intact, in enough quantity, reaching the right place, has never been tested in a living human. Nobody has measured it. Even granting the mouse data at face value, does a swallowed dose ever put enough of it in the right place to matter?

What conditions is KPV actually being discussed for

The lab case points toward gut inflammation first, because that’s where the one animal study was actually run. Skin and wound applications get discussed too, riding on alpha-MSH’s broader reputation in wound healing and pigmentation research. The wound-healing logic is borrowed from the parent molecule’s track record, not from anything tested with KPV directly. The gut logic has one dedicated study behind it. Neither has a human data point attached.

Where it sits legally, and what that means for anyone buying it

KPV, listed as both KPV free base and KPV acetate, sits on the FDA’s Pharmacy Compounding Advisory Committee docket for the July 23, 2026 meeting, filed under wound healing and inflammatory conditions (C7, C8). A docket listing means paperwork moved. It doesn’t mean anyone ran the study. It’s regulators deciding how a compound should be categorised for pharmacy compounding, a process that runs entirely separate from clinical trials or efficacy review. For anyone buying the compound today, purity and sourcing sit in the same grey zone every uncompounded peptide sits in: nobody outside the manufacturer is independently verifying what’s in the vial. On the anti-doping side, KPV doesn’t appear by name on the 2026 WADA Prohibited List and is generally treated as permitted (C9), which says something about how unremarkable its profile looks to regulators, not much about whether it works.

The bottom line

KPV has a genuinely coherent preclinical story. A credible mechanism for dialing down inflammation, one promising mouse result, and a plausible reason it might work without triggering the tanning response. None of that is nothing. But every piece of it sits on one side of a gap that has no bridge across it yet: no human trial, no measurement of how it moves through the body, no data point confirming any of the mouse biology survives the trip into a person.

If you’re weighing KPV now, that’s the honest picture. The mechanism makes sense. The proof it works in humans doesn’t exist yet. Whether the mouse result translates is still an open question, and you’d be the experiment, not the beneficiary of one.